Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed/refractory multiple myeloma

Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed/refractory multiple myeloma

Abstract Background Daratumumab is a human IgGκ monoclonal antibody targeting CD38 with direct on-tumor and immunomodulatory mechanisms of action. Daratumumab-based treatment is a standard of care for multiple myeloma (MM) based on data from randomized controlled trials. Real-world studies, such as...

Full description

Saved in:
Bibliographic Details
Main Authors: Luqun Wang, Wei Yang, Yafei Wang, Ting Niu, Rong Fu, Yuping Zhong, Wenbin Qian, Kaiyang Ding, Kai Sun, Hong Liu, Baijun Fang, Hui Liu, Yanhui Li, Yishen Yang, Jianmin Zhuo, Xi Chen, Canchan Cui, Jin Lu
Format: Article
Language:English
Published: BMC 2025-05-01
Series:BMC Cancer
Subjects:
Daratumumab
Immunomodulatory drugs
Multiple myeloma
Proteasome inhibitors
Real-world evidence
Overall response rate
Online Access:https://doi.org/10.1186/s12885-025-13925-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-13925-3

Similar Items